Clinical Feasibility & Validation of the Virtual Reality GlenxRose Speech-Language Therapies

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Alberta

About this trial

Factors related to successful rehabilitation are often directly related to adherence; for instance, dosage, frequency, and intensity can burden the patient regarding time and motivational factors. Furthermore, surrounding salience, patients may lose interest or find an intervention boring after a few sessions. It is well documented that nonadherence not only impacts rehabilitation for the patient but can also further prolong treatment, and increase hospital and clinician costs, in addition to a higher prevalence of future comorbidities. Therefore, strategies that improve patient adherence can significantly help optimize patient care and treatment outcomes.

One avenue to increase patient adherence is through the gamification of rehabilitation therapies using virtual reality (VR). Gamification of rehabilitation therapy can make mass practice required in rehabilitation therapies seemingly fun and more personally engaging for the patient. Additionally, the immersive experience achieved through VR can further promote salience and be customizable to individual patient requirements. As VR systems are now highly portable and relatively simple to utilize, they can provide an excellent opportunity to continue rehabilitation practice on the home front. Overall, the VR gamification of rehabilitation may increase adherence by shifting patients' perspectives of therapy as tedious, boring, or a hassle, to a fun and engaging game that ultimately helps their recovery processes.

The GlenXRose VR-delivered speech-language therapies (Cognitive Projections Lab, University of Alberta) have been developed and piloted in collaboration with the Glenrose Rehabilitation Hospital with the overall goal of increasing patient adherence, treatment outcomes, and satisfaction with vocal therapy. The proposed studies are to investigate the feasibility of implementing this technology in routine clinical care (specific to voice disorders), obtaining clinician feedback, examining associated financial costs, and continuing to examine the effect of the GlenXRose VR speech-language therapies on patient adherence and clinical outcomes, compared to traditional clinical care.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults receiving speech-language therapy at the Glenrose Rehabilitation Hospital (Edmonton, AB, Canada; Alberta Health Services)

Presence of a speech disorder

Proficiency in English

Able to provide signed informed consent to participate in the study

Disqualifiers

Severe cognitive impairments and/or behavioural impairments

Communication disorders that impact comprehension of verbal commands and understanding of scale used in the study

Previous history of neurological or psychiatric disorder

Substance use disorders

Trial design

Design model

Sequential

Treatments tested in this trial

  • GlenXRose Virtual Reality Speech Therapies

    Device

    Speech therapies for vocal cord disorders have been developed for virtual reality implementation. These include various games to interact with in a virtual environment while conducting rehabilitation therapy, in addition to educational visualizations

Treatment groups

30 Participants
are divided into 2 treatment groups
Group A: Virtual Reality Delivered Therapy + Standard Clinical CareExperimental treatment 1 intervention
Group B: Standard Clinical CareNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Change in Frequency and Treatment Adherence Rates

Reported Frequency of Rehabilitation Therapy

Time frame
Up to 12 Weeks
2

Change in Generalization

Self-reported time using voice production techniques

Time frame
Up to 12 Weeks
3

Change in Compliance Rate

Self-reported time (using a visual analog scale)

Time frame
Up to 12 Weeks
4

Change in Voice Handicap Index - 10

Quantification of participant reported perspectives of voice impairment(s)

Time frame
Up to 12 Weeks

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Alberta

Lead sponsor

Alberta Health services

Collaborator